In Vitro Anti-Inflammatory Activity of Selected Oxalate-Degrading Probiotic Bacteria: Potential Applications in the Prevention and Treatment of Hyperoxaluria

Journal of Food Science

Volumn 79, Issue 3, 2014, Pages

  Giardina, Silvana ^a   Scilironi, Cristina ^a   Michelotti, Angela ^a   Samuele, Alberta ^a   Borella, Fabio ^b   Daglia, Maria ^c   Marzatico, Fulvio ^c  

^a San Martino Siccomario   (Italy)

^b Neupharma srl   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Anti inflammatory cytokines; Hyperoxaluria; Lactic acid bacteria; Oxalate degrading activity; Probiotics

Indexed keywords

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PLANTARUM;

ANTIINFLAMMATORY AGENT; CALCIUM INTAKE; OXALIC ACID DERIVATIVE; PROBIOTIC AGENT;

BIFIDOBACTERIUM; CALCIUM INTAKE; COMPLICATION; DIET; HUMAN; HYPEROXALURIA; IN VITRO STUDY; INFLAMMATION; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; METABOLISM; MONONUCLEAR CELL;

ANTI-INFLAMMATORY AGENTS; BIFIDOBACTERIUM; CALCIUM, DIETARY; DIET; HUMANS; HYPEROXALURIA; IN VITRO TECHNIQUES; INFLAMMATION; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LEUKOCYTES, MONONUCLEAR; OXALATES; PROBIOTICS;

EID: 84895864082     PISSN: 00221147     EISSN: 17503841     Source Type: Journal    
DOI: 10.1111/1750-3841.12344     Document Type: Article

References (38)

1. Campieri M, Gionchetti P. 2001. Bacteria as the cause of ulcerative colitis. Gut 48:132-5.
2. Campieri C, Campieri M, Bertuzzi V, Swennen E, Matteuzzi D, Stefoni S, Pirovano F, Centi C, Ulisse S, Famularo G, De Simone C. 2001. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Intl 60:1097-105.
3. Chiang BL, Sheih YH, Wang LH, Liao CK, Gill HS. 2000. Enhancing immunity by dietary consumption of probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimisation and definition of cellular immune responses. Eur J Clin Nutr 54:849-55.
4. Clark JH, Fitzgerald JF, Bergstein JM. 1985. Nephrolithiasis in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 4:829-34.
5. Federici F, Vitali B, Gotti R, Pasca MR, Gobbi S, Peck AB, Brigidi P. 2004. Characterization and heterologous expression of the oxalyl coenzyme A decarboxylase gene from Bifidobacterium lactis. Appl Environ Microbiol 70(9):5066-73.
6. Fiocchi C. 1998. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182-205.
7. Guidelines for evaluation of probiotics in food: Joint FAO/WHO working group meeting, London, Ontario, Canada, 2002.
8. Gold LS, Slone TH, Ames BN. 2001. Natural and synthetic chemicals in the diet: a critical analysis of possible cancer hazards. In: Hester RE, Harrison RM, editors. Issues in environmental science and technology. Food safety and food quality. Cambridge, United Kingdom: The Royal Society of Chemistry. p 95-128.
9. Goldfarb DS. 2004. Microorganisms and calcium oxalate disease. Nephron Physiol 98:48-54.
10. Grentz L, Massey LK. 2002. Contribution of dietary oxalate to urinary oxalate in health and disease. Topics Clin Nutr 17:60-70.
11. Holmes RP, Assimos DG. 2004. The impact of dietary oxalate on kidney stone formation. Urol Res 32:311-16.
12. Holmes RP, Goodman HO, Assimos DG. 2001. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Intl 59:270-6.
13. Hoppe B, von Unruh G, Laube N, Hesse A, Sidhu H. 2005. Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria? Urol Res 33:372-5.
14. Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H. 2006. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Intl 70:1305-11.
15. Hoppe B, Beck BB, Milliner DS. 2009. The primary hyperoxalurias. Kidney Intl 75:1264-71.
16. Hungate, RE, Macy J. 1973. The roll-tube method for cultivation of strict anaerobes. Bulletins of the Ecological Research Committee:123-6.
17. Hylander E, Jarnun SS, Jensen HJ, Thale M. 1978. Enteric hyperoxaluria: dependence on small intestinal resection, colectomy and steatorrhea in chronic inflammatory bowel disease. Scand J Gastroenterol 13:577-88.
18. Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM, Cave DR. 2008. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 19:1197-1203.
19. Khaskhali MH, Bhanger MI, Khand FD.1996. Simultaneous determination of oxalic and citric acids in urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 675:147-51.
20. Klaver FA, van der Meer R. 1993. The assumed assimilation of cholesterol by lactobacilli and Bifidobacterium bifidum is due to their bile salt-deconjugating activity. Appl Environ Microbiol 59:1120-4.
21. Kurmann JA, Rasic JL. 1991. The health potential of products containing bifidobacteria. In Robinson R editor. Therapeutic properties of fermented milks. London: Elsevier Applied Science. p. 117-57.
22. Kwak C, Jeong BC, Ku JH, Kim HH, Lee JJ, Huh CS, Baek YJ, Lee SE. 2006. Prevention of nephrolithiasis by Lactobacillus in stone-forming rats: a preliminary study. Urol Res 34 265-70.
23. Liebman M, Al-Wahsh IA. 2011. Probiotics and other key determinants of dietary oxalate absorption. Adv Nutr 2(3):254-60.
24. Lieske JC, Goldfarb DS, De Simone C, Regnier C. 2005. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Intl 68:1244-49.
25. Marengo SR, Romani AM. 2008. Oxalate in renal stone disease: the terminal metabolite that just won't go away. Nat Clin Pract Nephrol 4:368-77.
26. Mathews LA, Doershuk CF, Stern RC, Resnick MI. 1996. Urolithiasis in cystic fibrosis. J Urol 155:1563-64.
27. Murphy C, Murphy S, O'Brien F, O'Donoghue M, Boileau T, Sunvold G, Reinhart G, Kiely B, Shanahan F, O'Mahony L. 2009. Metabolic activity of probiotics-oxalate degradation. Vet Microbiol 136:100-7.
28. Orrhage K, Nord CE. 2000. Bifidobacteria and lactobacilli in human health. Drugs Exp Clin Res 26:95-111.
29. Rothfuss KS, Stange EF, Herrlinger KR. 2006. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 12:4819-31.
30. Schreiber S, Heinig T, Thiele HG, Raedler A. 1995. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108:1434-44.
31. Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB. 2001. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes. J Urol 166:1487-91.
32. Streit J, Tran-Ho L, Königsberger E. 1998. Solubility of the three calcium oxalate hydrates in sodium chloride solutions and urine-like liquors. Monatsh Chem Chem Mon 129:1225-36.
33. Turroni S, Bendazzoli C, Dipalo SC, Candela M, Vitali B, Gotti R, Brigidi P. 2010. Oxalate-degrading activity in Bifidobacterium animalis subsp. lactis: impact of acidic conditions on the transcriptional levels of the oxalyl coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes. Appl Environ Microbiol 76:5609-20.
34. Verhulst A, De Broe ME, Oxalate 2008. Renal Injury from Drugs and Chemicals. In: De Broe ME, Porter GA, editors Clinical Nephrotoxins. New York: Springer. p 749-56.
35. Vervaet BA, Verhulst A, D'Haese PC, De Broe ME. 2009a. Nephrocalcinosis: new insights into mechanisms and consequences. Nephrol Dial Transplant 24:2030-35.
36. Vervaet BA, Verhulst A, Dauwe SE, De Broe ME, D'Haese PC. 2009b. An active renal crystal clearing mechanism in rat and man. Kidney Intl 75:41-51.
37. Weese JS, Weese HE, Yuricek L, Rousseau J. 2004. Oxalate degradation by intestinal lactic acid bacteria in dogs and cats. Vet Microbiol 101:161-6.
38. Worcester EM, Parks JH, Evan AP, Coe FL. 2006. Renal function in patients with nephrolithiasis. J Urol 176:600-3.